Clinical trial
A Phase II Randomized, Double-blind, Placebo-controlled, 26-week Study to Evaluate the Efficacy, Safety and Tolerability of GLPG1205 in Subjects With Idiopathic Pulmonary Fibrosis
NCT03725852 is registered in ClinicalTrials.gov with Lakefront Biotherapeutics NV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized, Double-blind, Placebo-controlled, 26-week Study to Evaluate the Efficacy, Safety and Tolerability of GLPG1205 in Subjects With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- Lakefront Biotherapeutics NV
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 27, 2018
- Completion date
- August 14, 2020
- Enrollment
- 68 (actual)
- Sites
- 36
Conditions
As the registry lists them; a condition with its own page is linked.